Program
xeruborbactam
Also written as “Cefiderocol/Xeruborbactam”, “Xeruborbactam” and “Xeruborbactam/Cefiderocol”.
Its studies are mostly in Bacterial Infections, led by Shionogi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 30 open or running | phase 1since Aug 2, 2024 | Aug 2, 2024 | none ahead |
Also a collaborator on its studies: shionogi-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 2, 2024First study: phase 1 study in Bacterial InfectionsFirst studyNCT06547554 · 60 enrolled · United States
- Jul 11, 20252 phase 1 studiesNCT07083817, NCT07104162
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07104162Bacterial Infections · United States | 1 | Completed | Sep 4, 2026 | 40 |
| NCT07083817ADME · United Kingdom | 1 | Completed | Aug 27, 2025 | 8 |
| NCT06547554Bacterial Infections · United States | 1 | Completed | Oct 27, 2025 | 60 |
How it is read
Names in the registry
- “Cefiderocol/Xeruborbactam”, 1 entry
- “Xeruborbactam”, 1 entry
- “Xeruborbactam/Cefiderocol”, 1 entry
- “[14C]Xeruborbactam”, 1 entry
Conditions, from the studies’ own filings
- Bacterial Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.